

# HR for Mortality from CVD For Log UTXB by ASA Group

## The PHREG Procedure

Aspirin Use=No Aspirin Use

Model Information	
Data Set	WORK.SURVIVALCVD
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1681
Number of Observations Used	1413

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
1413	45	1368	96.82

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	640.354	624.213
AIC	640.354	626.213
SBC	640.354	628.020

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	16.1409	1	<.0001
Score	15.0168	1	0.0001
Wald	15.4135	1	<.0001

Analysis of Maximum Likelihood Estimates						
Parameter	DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio
logtxb	1	0.82405	0.20990	15.4135	<.0001	2.280

**HR for Mortality from CVD For Log UTXB by ASA Group****The PHREG Procedure**

Aspirin Use=No Aspirin Use

Hazard Ratios for logtxb			
Description	Point Estimate	95% Wald Confidence Limits	
logtxb Unit=1	2.280	1.511	3.440

# HR for Mortality from CVD For Log UTXB by ASA Group

## The PHREG Procedure

Aspirin Use=Aspirin Use

Model Information	
Data Set	WORK.SURVIVALCVD
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1363
Number of Observations Used	1062

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
1062	88	974	91.71

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	1192.338	1187.835
AIC	1192.338	1189.835
SBC	1192.338	1192.313

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	4.5024	1	0.0338
Score	4.8784	1	0.0272
Wald	4.8827	1	0.0271

Analysis of Maximum Likelihood Estimates						
Parameter	DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio
logtxb	1	0.34647	0.15679	4.8827	0.0271	1.414

**HR for Mortality from CVD For Log UTXB by ASA Group****The PHREG Procedure**

Aspirin Use=Aspirin Use

Hazard Ratios for logtxb			
Description	Point Estimate	95% Wald Confidence Limits	
logtxb Unit=1	1.414	1.040	1.923

## The PHREG Procedure

Model Information	
Data Set	WORK.SURVIVALCVD
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	3044
Number of Observations Used	2475

Class Level Information		
Class	Value	Design Variables
q2u	Q4	1
	Q1-Q3	0

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
2475	133	2342	94.63

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	2033.121	2001.741
AIC	2033.121	2003.741
SBC	2033.121	2006.631

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	31.3802	1	<.0001
Score	37.0971	1	<.0001
Wald	34.0418	1	<.0001

## The PHREG Procedure

Type 3 Tests			
Effect	DF	Wald Chi-Square	Pr > ChiSq
q2u	1	34.0418	<.0001

Analysis of Maximum Likelihood Estimates								
Parameter		DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	Label
q2u	Q4	1	1.02042	0.17489	34.0418	<.0001	2.774	4th Q vs Q1-3 Q4

Hazard Ratios for 4th Q vs Q1-3			
Description	Point Estimate	95% Wald Confidence Limits	
q2u Q4 vs Q1-Q3	2.774	1.969	3.909

## The PHREG Procedure

Aspirin Use=No Aspirin Use

Model Information	
Data Set	WORK.SURVIVALCVD
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1681
Number of Observations Used	1413

Class Level Information		
Class	Value	Design Variables
q2u	Q4	1
	Q1-Q3	0

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
1413	45	1368	96.82

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	640.354	616.177
AIC	640.354	618.177
SBC	640.354	619.983

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	24.1774	1	<.0001
Score	30.0757	1	<.0001
Wald	25.0190	1	<.0001

## The PHREG Procedure

Aspirin Use=No Aspirin Use

Type 3 Tests			
Effect	DF	Wald Chi-Square	Pr > ChiSq
q2u	1	25.0190	<.0001

Analysis of Maximum Likelihood Estimates								
Parameter		DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	Label
q2u	Q4	1	1.50117	0.30012	25.0190	<.0001	4.487	4th Q vs Q1-3 Q4

Hazard Ratios for 4th Q vs Q1-3			
Description	Point Estimate	95% Wald Confidence Limits	
q2u Q4 vs Q1-Q3	4.487	2.492	8.080



## The PHREG Procedure

Aspirin Use=Aspirin Use

Model Information	
Data Set	WORK.SURVIVALCVD
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1363
Number of Observations Used	1062

Class Level Information		
Class	Value	Design Variables
q2u	Q4	1
	Q1-Q3	0

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
1062	88	974	91.71

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	1192.338	1181.298
AIC	1192.338	1183.298
SBC	1192.338	1185.775

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	11.0399	1	0.0009
Score	12.5853	1	0.0004
Wald	11.9931	1	0.0005

## The PHREG Procedure

Aspirin Use=Aspirin Use

Type 3 Tests			
Effect	DF	Wald Chi-Square	Pr > ChiSq
q2u	1	11.9931	0.0005

Analysis of Maximum Likelihood Estimates								
Parameter		DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	Label
q2u	Q4	1	0.76273	0.22025	11.9931	0.0005	2.144	4th Q vs Q1-3 Q4

Hazard Ratios for 4th Q vs Q1-3			
Description	Point Estimate	95% Wald Confidence Limits	
q2u Q4 vs Q1-Q3	2.144	1.392	3.302